COVID Shot Transmits Aerosolized Antibodies to Those Who’ve Not Gotten It: Study

by Carolyn Hendler, JD and Barbara Loe Fisher

Published August 21, 2023
Vaccines

A peer reviewed study recently published in Immunohorizons has provided evidence that individuals, who received messenger RNA (mRNA) COVID-19 shots, are able to transmit aerosolized antibodies to unvaccinated individuals. The study, which was originally reported in preprint in May 2022, looked at masks worn for one day by laboratory workers who received a COVID shot. Researchers found both Immunoglobulin G (IgG) and Immunoglobulin A (IgA) antibodies of SARS-CoV-2 on the masks and also concluded that droplet aerosolized antibodies may be passively transferred from immune and non-immune individuals.¹ ²

This study confirmed findings of previous studies that have shown that individuals who received COVID shots have high levels of intranasal IgG and IgA antibodies to the SARS CoV-2 virus and that these intranasal antibodies can be transferred to others through aerosols and respiratory droplets.³ ⁴ The authors of the study suggested their findings may indicate that COVID shots play a positive role in transferring passive immunity to SARS-CoV-2 to those who do not get the shot.⁵

Parents Passed SARS-CoV-2 IgG Antibodies to Children

The study examined nasal swabs of children living with family members who received COVID shots, and compared them to nasal swabs of children living with with family members who did not. SARS-CoV-2 specific IgG antibodies were readily detected in the nasal swabs of children living in households who received COVID shots. There was a significant association between parents, who had a high number of SARS-CoV-2 specific intranasal IgG antibodies, and their children, who also showed a high number of intranasal IgA antibodies.⁶

The authors of the study said:

The simplest interpretation of our results is that (1) aerosol transmission of Ab can occur and that (2) the propensity for this transfer is, unsurprisingly, directly related to the amount of nasal/oral Ab found within those in the population possessing immunity.⁷

People Who Get COVID Shot May Excrete Spike Protein to Those Who Did Not Get a COVID Shot

A 2022 report in Infectious Disease Research hypothesized that individuals, who have received COVID shots that contain synthetic mRNA coated in lipid nanoparticles, could theoretically excrete and transmit to others (1) lipid nanoparticles containing mRNA (2) the vaccine mRNA or (3) the spike protein translated by the cells of the vaccinee.

The authors suggest the synthetic mRNA coated in lipid nanoparticles—or the spike protein that the cells have been programmed to make—could be inhaled, absorbed transcutaneously or otherwise transferred to an individual who has not gotten a COVID shot. In other words, unlike traditional shedding and transmission of vaccine strain virus via live attenuated oral polio, rotavirus or influenza vaccines, there may be excretion and transmission of the lipid nanoparticles containing mRNA of the virus or of the spike protein produced by the cells of those who get the shot. Excretion is the dissemination of the vector through bodily secretions.⁸

Excretion Studies Required for Products That Direct Cells to Make Proteins

Although mRNA biologicals targeting the mutated coronavirus are referred to as “vaccines,” some scientists have suggested that the products should more appropriately be described and treated by regulatory agencies as genetic therapeutic drugs.⁹ Moderna, a drug company that partnered with the U.S. National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop Spikevax mRNA COVID biologic defines “mRNA therapy” as “a set of instructions that direct cells in the body to make proteins to prevent or fight disease.”¹⁰

The authors of the 2022 report pointed out:

The massive COVID-19 vaccination campaign is the first time that mRNA vaccines have been used on a global scale. The mRNA vaccines correspond exactly to the definition of gene therapy of the American and European regulatory agencies. The regulations require excretion studies of these drugs and their products (the translated proteins). These studies have not been done for mRNA vaccines (nor for adenovirus vaccines). There are numerous reports of symptoms and pathologies identical to the adverse effects of mRNA vaccines in unvaccinated persons in contact with freshly vaccinated persons. It is therefore important to review the state of knowledge on the possible excretion of vaccine nanoparticles as well as mRNA and its product, the spike protein.

Despite the recommendation from regulators in other gene therapy trials, mRNA COVID shot trials conducted by Moderna and Pfizer/BioNTech did not study the excretion of lipid nanoparticle coated mRNA or the spike protein produced by vaccinated persons.

According to the author of the report, mRNA shots fall under the definition of gene therapy products pursuant to the 2015 U.S. Food and Drug Administration (FDA) definition and should, therefore, have undergone the same clinical trial requirements as other gene therapy products. However, since the COVID shots were labeled by manufacturers and governments as “vaccines,” drug companies were able to avoid the clinical trial requirements for gene therapy products, including the study of excretion by all body fluids such as saliva, sputum, urine, semen and breast milk excretion as well as through skin and feces.¹¹

An analysis of the Immunohorizons report references Pfizer documents from the Phase I/II/III trial of the company’s Comirnaty mRNA COVID biologic, which mentions the possibility that the shot could be transmissible by way of skin contact, inhalation, breast milk, and semen. The Pfizer documents state that pregnant women could be exposed to the experimental product by way of environmental exposure including inhalation or skin contact.¹²

The author writes:

This clearly means that any contact, including sexual contact with someone who has received the vaccines, exposes those who have not received the vaccines to the “intervention”, i.e. mRNA.¹³

In-depth research into the transmissibility of ingredients and by-products of mRNA biologics is urgently needed considering the accelerated development of more mRNA biological products that will be used in the future. Currently, mRNA biologics are being developed for influenza, Lyme disease, HIV, Zika virus, yellow fever, rabies and tuberculosis.¹⁴ ¹⁵ ¹⁶ ¹⁷

If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.

Click here to view References:

Templeton Times

Friday, August 25, 2023